title: Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy.
abstract: Somatostatin receptors have been described on the membrane of neoplastic cells derived from the APUD system and their expression has also been demonstrated on small cell lung cancer (SCLC) in vitro and in vivo. 21 patients with SCLC were studied using 111In-octreotide (111In-OCT) scintigraphy. Scintigraphic examinations were performed following intravenous (i.v.) injection of 111 MBq 111In-OCT with whole-body scintigraphy and planar scintigraphy of the thorax as well as the SPET technique. No short-term side effects were described following 111In-OCT administration. We studied the 111In-OCT biodistribution in 3 patients with serial scintigraphies at 1, 5 and 24 h. We used the 5 h as standard scanning time for the following 18 patients. The scintigraphic results were compared with those of other conventional diagnostic procedures. 111In-OCT detected 86% (48/56) of the lesions already known at the time of scintigraphy. It was positive in all 20 SCLC patients and negative in one lung adenocarcinoma. 111In-OCT showed high sensitivity for mediastinal metastases (94%) and good sensitivity for bone metastases (75%) and abdominal lymph node metastases (71%). 111In-OCT did not detect two liver metastases. 111In-OCT detected five unknown lesions which were confirmed by other diagnostic examinations. 111In-OCT was also effective in cancer patients with low levels of NSE. Our study shows that 111In-OCT scintigraphy is a reliable, non-invasive technique to detect primary SLCL and its locoregional or distant metastases. The clinical utility of receptor status characterisation obtained with 111In-OCT scintigraphy should be evaluated by means of an appropriate prospective study.
authors.affiliation: Department of Nuclear Medicine, Istituto Nazionale Tumori, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Bombardieri
authors.forename: F
authors.initials: F
authors.lastname: Crippa
authors.forename: I
authors.initials: I
authors.lastname: Cataldo
authors.forename: A
authors.initials: A
authors.lastname: Chiti
authors.forename: E
authors.initials: E
authors.lastname: Seregni
authors.forename: E
authors.initials: E
authors.lastname: Soresi
authors.forename: R
authors.initials: R
authors.lastname: Boffi
authors.forename: G
authors.initials: G
authors.lastname: Invernizzi
authors.forename: G L
authors.initials: GL
authors.lastname: Buraggi
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000737:chemistry / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008175:Lung Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives*; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin
chemical_list: D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide